SCHEMBL3136549

SCHEMBL3136549

COC(=O)C=C(C)CO

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4434083 1.00
SCHEMBL13751256 0.84 HCAR2 (0.48)
SCHEMBL29053147 0.81 HCAR2 (0.40)
SCHEMBL1194992 0.81 HCAR2 (0.40)
SCHEMBL1194995 0.81 HCAR2 (0.40)
SCHEMBL9912439 0.80
SCHEMBL9483378 0.80
SCHEMBL3135210 0.80
SCHEMBL9654807 0.80
SCHEMBL4424904 0.80

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12473295-B2 Substituted straight chain spiro derivatives JANSSEN PHARMACEUTICA NV (BE) 2025-11-18 US disclosed
CN-118344372-A Substituted straight-chain spiro derivatives 詹森药业有限公司 2024-07-16 CN disclosed
CN-118255773-A Substituted straight-chain spiro derivatives 詹森药业有限公司 2024-06-28 CN disclosed
CN-118255774-A Substituted straight-chain spiro derivatives 詹森药业有限公司 2024-06-28 CN disclosed
US-20230142285-A1 SUBSTITUTED STRAIGHT CHAIN SPIRO DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2023-05-11 US disclosed
US-20230142285-A1 SUBSTITUTED STRAIGHT CHAIN SPIRO DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2023-05-11 US disclosed
EP-4077312-A1 SUBSTITUTED STRAIGHT CHAIN SPIRO DERIVATIVES Janssen Pharmaceutica NV (BE) 2022-10-26 EP disclosed
CN-114867721-A Substituted straight-chain spiro derivatives 詹森药业有限公司 2022-08-05 CN disclosed
WO-2021121327-A1 SUBSTITUTED STRAIGHT CHAIN SPIRO DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2021-06-24 WO disclosed
CN-103958526-B Pyrimidinediamine derivative, preparation method and medical application thereof SHANGHAI HENGRUI PHARMACEUTICAL CO.,LTD. (CN) 2015-09-09 CN disclosed
CN-103958526-A Pyrimidinediamine derivative, preparation method and medical application thereof SHANGHAI HENGRUI PHARM CO LTD 2014-07-30 CN disclosed
EP-1697388-B1 METHOD FOR PRODUCING PHOSPHONIUM SALTS BASF SE (DE) 2010-07-21 EP disclosed
US-7547807-B2 Method for producing phosphonium salts BASF SE (DE) 2009-06-16 US disclosed
US-20070123726-A1 Method for producing phosphonium salts BASF AKTIENGESELLSCHAFT PATENTS, TRADEMARKS AND LICENSES (DE) 2007-05-31 US disclosed
EP-1697388-A1 METHOD FOR PRODUCING PHOSPHONIUM SALTS BASF AKTIENGESELLSCHAFT (DE) 2006-09-06 EP disclosed
WO-2005058924-A1 METHOD FOR PRODUCING PHOSPHONIUM SALTS BASF AKTIENGESELLSCHAFT (DE) 2005-06-30 WO disclosed
EP-1449835-A2 Alpha-substituted pyrimidine-thioalkyl and alkylether compounds PHARMACIA &amp; UPJOHN COMPANY (US) 2004-08-25 EP disclosed
US-6043248-A VIRICIDES FOR TREATING AN INDIVIDUAL INFECTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS PHARMACIA & UPJOHN COMPANY (US) 2000-03-28 US disclosed
EP-0824524-A1 ALPHA-SUBSTITUTED PYRIMIDINE-THIOALKYL AND ALKYLETHER COMPOUNDS AS INHIBITORS OF VIRAL REVERSE TRANSCRIPTASE PHARMACIA &amp; UPJOHN COMPANY (US) 1998-02-25 EP disclosed
WO-1996035678-A1 ALPHA-SUBSTITUTED PYRIMIDINE-THIOALKYL AND ALKYLETHER COMPOUNDS AS INHIBITORS OF VIRAL REVERSE TRANSCRIPTASE PHARMACIA & UPJOHN COMPANY (US) 1996-11-14 WO disclosed